Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.78 |
| ▸ | LMNA | P02545 | 2/20 | 0.78 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.78 |
| ▸ | HTR1A | P08908 | 2/20 | 0.78 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.78 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.78 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.78 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.78 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.78 |
| ▸ | DRD1 | P21728 | 2/20 | 0.78 |
| ▸ | HTR2A | P28223 | 2/20 | 0.78 |
| ▸ | HTR2C | P28335 | 2/20 | 0.78 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.78 |
| ▸ | HRH1 | P35367 | 2/20 | 0.78 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.78 |
| ▸ | DRD3 | P35462 | 2/20 | 0.78 |
| ▸ | HTR2B | P41595 | 2/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.78 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12287533 | 0.90 | DRD2 (0.80) | DRD2LMNACHRM2HTR1AADRA2A | |
| SCHEMBL8301867 | 0.89 | DRD2 (0.76) | DRD2LMNACHRM2HTR1AADRA2A | |
| SCHEMBL13114628 | 0.89 | DRD2 (0.78) | DRD2LMNACHRM2HTR1AADRA2A | |
| SCHEMBL20959758 | 0.89 | CHRM1 (0.66) | DRD2LMNACHRM2HTR1AADRA2A | |
| SCHEMBL16884483 | 0.89 | DRD2 (0.74) | DRD2LMNACHRM2HTR1AADRA2A | |
| Quetiapine SCHEMBL27866344 | 0.88 | DRD2 (0.96) | DRD2LMNACHRM2HTR1AADRA2A | |
| Quetiapine SCHEMBL7932 | 0.88 | DRD2 (1.00) | DRD2LMNACHRM2HTR1AADRA2A | |
| Quetiapine SCHEMBL4283801 | 0.88 | DRD2 (1.00) | DRD2LMNACHRM2HTR1AADRA2A | |
| Quetiapine SCHEMBL4638768 | 0.88 | DRD2 (1.00) | DRD2LMNACHRM2HTR1AADRA2A | |
| Quetiapine SCHEMBL29360153 | 0.88 | DRD2 (1.00) | DRD2LMNACHRM2HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150191430-A1 | CONJUGATES OF HUPERZINE AND ANALOGS THEREOF | BISCAYNE NEUROTHERAPEUTICS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-8828993-B2 | Psychotropic agents having glutamate NMDA activity | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2014-09-09 | — | — | US | disclosed |
| US-8828993-B2 | Psychotropic agents having glutamate NMDA activity | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2014-09-09 | — | — | US | disclosed |
| US-20130131048-A1 | NOVEL PSYCHOTROPIC AGENTS HAVING GLUTAMATE NMDA ACTIVITY | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2013-05-23 | — | — | US | disclosed |
| US-20130131048-A1 | NOVEL PSYCHOTROPIC AGENTS HAVING GLUTAMATE NMDA ACTIVITY | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2013-05-23 | — | — | US | disclosed |
| US-8394790-B2 | Psychotropic agents having glutamate NMDA activity | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2013-03-12 | — | — | US | disclosed |
| US-8394790-B2 | Psychotropic agents having glutamate NMDA activity | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2013-03-12 | — | — | US | disclosed |
| US-7858777-B2 | Preparation method for quetiapine | FERMION OY (FI) | 2010-12-28 | — | — | US | disclosed |
| US-20100093704-A1 | NOVEL PSYCHOTROPIC AGENTS HAVING GLUTAMATE NMDA ACTIVITY | RAMOT AT TEL-AVIV UNIVERSITY LTD (IL) | 2010-04-15 | — | — | US | disclosed |
| US-20100093704-A1 | NOVEL PSYCHOTROPIC AGENTS HAVING GLUTAMATE NMDA ACTIVITY | RAMOT AT TEL-AVIV UNIVERSITY LTD (IL) | 2010-04-15 | — | — | US | disclosed |
| WO-2008050341-A2 | NOVEL PSYCHOTROPIC AGENTS HAVING GLUTAMATE NMDA ACTIVITY | RAMOT AT TEL-AVIV UNIVERSITY LTD (IL) | 2008-05-02 | — | — | WO | disclosed |
| US-20070111986-A1 | Preparation method for quetiapine | FERMION OY (FI) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191430-A1 | CONJUGATES OF HUPERZINE AND ANALOGS THEREOF | HTT, HNMT, GAP43 | DRD2 2057/4885LMNA 748/4885CHRM2 1699/4885 |
| US-20130131048-A1 | NOVEL PSYCHOTROPIC AGENTS HAVING GLUTAMATE NMDA ACTIVITY | GRIN1, GRIN2A, GRIN2B | DRD2 94/4885LMNA 4848/4885CHRM2 484/4885 |
| US-20100093704-A1 | NOVEL PSYCHOTROPIC AGENTS HAVING GLUTAMATE NMDA ACTIVITY | GRIN1, GRIN2A, GRIN2B | DRD2 94/4885LMNA 4848/4885CHRM2 484/4885 |
| US-20070111986-A1 | Preparation method for quetiapine | CYP3A5, COMT, CYP51A1 | DRD2 56/4885LMNA 770/4885CHRM2 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.